# 2026年1月22日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 整合应激反应与药物诱导的急性肾损伤：ATF4-STAT1-GBP2 信号通路的参与

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41563239)
**期刊：** Journal of the American Society of Nephrology : JASN
**PMID：** 41563239
**DOI：** 10.1681/ASN.0000000984

### 第一部分 原文与翻译

**英文原标题：** Integrated Stress Response and Drug-Induced Acute Kidney Injury: Involvement of ATF4-STAT1-GBP2 Signaling.

> **英文摘要：**
> BACKGROUND: Pyroptosis plays a critical role in eliminating pathogens and facilitating tissue repair; however, sustained pyroptosis-driven inflammation accelerates kidney injury and disease progression. Thus, elucidating the mechanisms governing pyroptosis is essential for developing effective therapies for inflammatory kidney diseases such as acute kidney injury (AKI), which currently lacks specific treatment options. METHODS: Changes in tubular epithelial cells following drug-induced AKI were assessed using single-cell RNA sequencing, immunohistochemistry, and immunofluorescence. Mechanistic insights were obtained through RNA sequencing, genomic manipulation, transcriptomic profiling, luciferase reporter assays, co-immunoprecipitation, and Western blotting. Tubular epithelial cell fate was further evaluated using transgenic mouse models and pharmacological interventions. RESULTS: We identified activating transcription factor 4 (ATF4) as a key regulator of inflammation in drug-induced AKI. As the master regulator of the integrated stress response, ATF4 was markedly upregulated in renal tubules and positively correlated with kidney dysfunction in both human and murine AKI models. The specific deletion of ATF4 in tubular epithelial cells significantly ameliorated kidney dysfunction, inflammation, and mitochondrial apoptosis, whereas ATF4 activation exacerbated these pathological features. Mechanistically, ATF4 suppression inhibited STAT1 phosphorylation and disrupted its interaction with GBP2, thereby attenuating NLRP3 inflammasome activation, preventing tubular epithelial cells' pyroptosis, and improving kidney function. Notably, inhibition of ATF4-either pharmacologically using our prioritized integrated stress response antagonist ERMT1 or through engineered nanobiologics-mediated silencing of tubular epithelial cells-significantly reduced renal inflammation and injury. CONCLUSIONS: ATF4 promoted pyroptosis in drug-induced AKI through STAT1-GBP2 signaling.

> **中文摘要：**
> 背景：细胞焦亡在清除病原体和促进组织修复中起着至关重要的作用；然而，持续的焦亡驱动的炎症会加速肾脏损伤和疾病进展。因此，阐明控制细胞焦亡的机制对于开发炎症性肾脏疾病（如目前缺乏特异性治疗方案的急性肾损伤，AKI）的有效疗法至关重要。方法：利用单细胞RNA测序、免疫组化和免疫荧光评估药物诱导的AKI后肾小管上皮细胞的变化。通过RNA测序、基因组操纵、转录组学分析、荧光素酶报告基因检测、共免疫沉淀和蛋白质印迹法获得机制见解。利用转基因小鼠模型和药理学干预进一步评估肾小管上皮细胞的命运。结果：我们确定激活转录因子4（ATF4）是药物诱导的AKI中炎症的关键调节因子。作为整合应激反应的主要调节因子，ATF4在人类和小鼠AKI模型的肾小管中均显著上调，并与肾功能障碍呈正相关。在肾小管上皮细胞中特异性缺失ATF4可显著改善肾功能障碍、炎症和线粒体凋亡，而ATF4激活则加剧了这些病理特征。机制上，抑制ATF4可抑制STAT1磷酸化并干扰其与GBP2的相互作用，从而减轻NLRP3炎性体激活，防止肾小管上皮细胞焦亡，并改善肾功能。值得注意的是，通过药理学抑制ATF4——无论是使用我们优先考虑的整合应激反应拮抗剂ERMT1，还是通过工程化纳米生物制剂介导的肾小管上皮细胞基因沉默——均显著减轻了肾脏炎症和损伤。结论：ATF4通过STAT1-GBP2信号传导促进药物诱导的AKI中的细胞焦亡。

### 第二部分 AI 大师评价

本研究深入探讨了整合应激反应（ISR）核心因子ATF4在药物诱导急性肾损伤（AKI）中的致病机制。研究通过单细胞测序、转基因模型及功能实验，揭示了ATF4通过调控STAT1-GBP2轴激活NLRP3炎性体并触发肾小管上皮细胞焦亡的关键路径。其创新性在于不仅阐明了细胞应激与焦亡的分子衔接，还展示了新型拮抗剂ERMT1和工程化纳米生物制剂的治疗潜力，为临床上缺乏特异性药物的AKI提供了精准干预的新靶点。

---

## 2. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 3. Mzb1通过诱导内质网应激促进血吸虫病的进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41562889)
**期刊：** The Journal of infectious diseases
**PMID：** 41562889
**DOI：** 10.1093/infdis/jiaf639

### 第一部分 原文与翻译

**英文原标题：** Mzb1 Promotes Progression of Schistosomiasis by Inducing Endoplasmic Reticulum Stress.

> **英文摘要：**
> BACKGROUND: Despite advances in anthelmintic therapy, there are currently no effective treatments for schistosomiasis-induced liver fibrosis. Previous studies have reported elevated marginal zone B and B1 cell specific protein (MZB1) expression in fibrotic diseases, but its function remains unclear, and its role in schistosomiasis has not been investigated. This study aimed to explore the function and mechanism of MZB1 in Schistosoma japonicum infection. METHODS: We evaluated the expression of Mzb1 in the liver and spleen of Schistosoma-infected mice using methods such as Western blot, qPCR, and immunohistochemistry. We also employed adeno-associated virus (AAV) to knock down Mzb1 gene expression, assessing the role of Mzb1 in the progression of schistosomiasis and its downstream pathways. Additionally, in vivo experiments were conducted using downstream endoplasmic reticulum stress agonists and inhibitors to evaluate the role of this pathway in the progression of schistosomiasis. RESULTS: Our findings demonstrated that Mzb1 was significantly upregulated in the liver and spleen tissues of infected mice. Knockdown of Mzb1 markedly reduced liver fibrosis and splenomegaly. Mzb1 was predominantly expressed in CD20-positive B cells and was found to activate endoplasmic reticulum (ER) stress. Inhibition of ER stress alleviated liver fibrosis and splenomegaly, while activation of ER stress exacerbated these pathological conditions and reversed the protective effects of Mzb1 knockdown. CONCLUSIONS: We identified Mzb1 as a key factor that promotes liver fibrosis and splenomegaly in schistosomiasis through the activation of ER stress. This novel pathogenic mechanism may provide a potential therapeutic target for the treatment of schistosomiasis-induced liver fibrosis.

> **中文摘要：**
> 背景：尽管抗蠕虫治疗取得了进展，但目前对于血吸虫病诱导的肝纤维化尚无有效治疗方法。以往的研究报告了在纤维化疾病中边缘区B细胞和B1细胞特异性蛋白（MZB1）的表达升高，但其功能尚不清楚，且其在血吸虫病中的作用尚未得到研究。本研究旨在探讨MZB1在日本血吸虫感染中的功能及其机制。方法：我们通过蛋白质印迹（Western blot）、定量聚合酶链反应（qPCR）和免疫组织化学等方法评估了感染血吸虫小鼠肝脏和脾脏中Mzb1的表达。我们还采用腺相关病毒（AAV）敲低Mzb1基因表达，评估Mzb1在血吸虫病进展及其下游通路中的作用。此外，利用下游内质网应激激动剂和抑制剂进行了体内实验，以评估该通路在血吸虫病进展中的作用。结果：我们的研究结果表明，感染小鼠的肝脏和脾脏组织中Mzb1显著上调。敲低Mzb1显著减轻了肝纤维化和脾肿大。Mzb1主要在CD20阳性B细胞中表达，并被发现可激活内质网（ER）应激。抑制内质网应激可缓解肝纤维化和脾肿大，而激活内质网应激则加剧了这些病理状况，并逆转了敲低Mzb1的保护作用。结论：我们确定Mzb1是通过激活内质网应激促进血吸虫病肝纤维化和脾肿大的关键因子。这一新颖的致病机制可能为血吸虫病诱导的肝纤维化治疗提供潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究揭示了Mzb1蛋白在血吸虫病肝纤维化和脾肿大中的核心促病作用，并阐明了其通过在CD20+ B细胞中诱导内质网应激这一分子机制。研究通过基因敲低和药理学干预手段，严谨地验证了Mzb1-ER应激轴在病理过程中的必要性与充分性。该发现不仅填补了Mzb1在寄生虫性肝纤维化中功能的空白，也为临床开发针对日本血吸虫病及其相关器官损伤的新型治疗靶点提供了坚实的科学依据。

---

## 4. 心源性休克幸存者的精神健康后遗症及管理：一项全国性的人群研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559811)
**期刊：** Critical care (London, England)
**PMID：** 41559811
**DOI：** 10.1186/s13054-026-05841-0

### 第一部分 原文与翻译

**英文原标题：** Mental health sequelae and management in survivors of cardiogenic shock: a nationwide population-based study.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究通过全国性的大规模人群数据库，深入探讨了心源性休克幸存者在生理康复后所面临的精神健康后遗症及其临床管理现状。研究聚焦于这一危重症群体长期预后中的心理健康维度，填补了心源性休克随访管理中关于精神负担的认知空白。尽管具体摘要内容缺失，但从其研究设计来看，对于完善心源性休克患者的全周期医疗管理体系具有重要的流行病学指导价值，强调了多学科随访的必要性。

---

## 5. 脑死亡判定中的药理学与毒理学干扰因素：多学科指南

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559743)
**期刊：** Critical care (London, England)
**PMID：** 41559743
**DOI：** 10.1186/s13054-025-05833-6

### 第一部分 原文与翻译

**英文原标题：** Pharmacologic and toxicologic confounders in brain death determination: a multidisciplinary guide.

> **英文摘要：**
> BACKGROUND: The assessment of comatose ICU patients presents several challenges with respect to the etiology, depth and ultimate outcome. The acceptance in 1959 of the worst-outcome scenarios of coma, i.e. brain death, and the publication of the Harvard Brain Death Criteria in 1968, were key developments in the management of irreversible coma. Pharmacologic confounders often complicate coma assessments, including brain-death determination. Moreover, associated clinical factors during coma, such as organ failure, hypothermia, prolonged continuous infusions, intoxication, and extreme obesity often alter drug metabolism and clearance. Such circumstances may further complicate standard assessments, and guideline recommendations often do not account for altered pharmacokinetics and pharmacodynamics. MAIN TEXT: The assessment of comatose patients involves complex pharmacologic considerations that significantly impact diagnostic accuracy. Accurate differentiation between pharmacologic, metabolic, and structural causes of coma is essential, particularly since drug-related unconsciousness generally carries a more favorable prognosis than other etiologies. Nonetheless, for best outcomes, it is imperative that the etiology of any drug-induced coma be determined as early as possible. It is important to recognize, however, that routine toxicology screens are not comprehensive. Additionally, the interplay between hypothermia and drug metabolism poses unique challenges, as core temperature significantly affects pharmacokinetic parameters such as hepatic metabolism, leading to reduced drug clearance. Multiorgan dysfunction, common after severe neurological injury, further complicates these assessments. Overdose scenarios introduce additional complexity. While ancillary testing may aid in diagnosis of brain death, they have limitations, particularly in cases of profound intoxication. Additionally, premature use of ancillary testing could lead to misdiagnosis. This review is organized into two main sections: Part I examines general coma and its associated pharmacologic considerations, followed by Part II which focuses on brain death. CONCLUSION: Accurate assessment of coma and brain death often requires a multidisciplinary approach, integrating expertise in neurology, pharmacy, critical care, and toxicology. Current brain death guidelines provide a framework but leave open critical gaps in pharmacologic and toxicologic confounders. This review article highlights the importance of multidisciplinary approach to the care of coma and brain death patients and further research to refine diagnostic accuracy and mitigate the risks of premature brain death declarations.

> **中文摘要：**
> 背景：ICU 昏迷患者的评估在病因、深度和最终结局方面面临多重挑战。1959 年对昏迷最差结局方案（即脑死亡）的认可，以及 1968 年哈佛脑死亡标准的发布，是不可逆性昏迷管理中的关键进展。药理学干扰因素常使昏迷评估（包括脑死亡判定）变得复杂。此外，昏迷期间相关的临床因素，如器官衰竭、低温、长时间持续输注、中毒和重度肥胖，常会改变药物代谢和清除。这些情况可能进一步增加标准评估的复杂性，且指南建议往往未考虑药代动力学和药效学的改变。正文：昏迷患者的评估涉及复杂的药理学考量，这些考量显著影响诊断准确性。准确区分昏迷的药理学、代谢性和结构性病因至关重要，特别是由于药物相关的意识丧失通常比其他病因具有更好的预后。尽管如此，为了获得最佳结果，必须尽早确定任何药物诱导昏迷的病因。然而，重要的是要认识到常规毒理学筛选并不全面。此外，低温与药物代谢之间的相互作用构成了独特的挑战，因为核心体温会显著影响药代动力学参数（如肝脏代谢），导致药物清除率降低。严重神经损伤后常见的多器官功能障碍进一步增加了这些评估的复杂性。过量用药的情景则引入了额外的复杂性。虽然辅助测试可能有助于脑死亡的诊断，但它们也存在局限性，特别是在深度中毒的情况下。此外，过早使用辅助测试可能导致误诊。本综述分为两个主要部分：第一部分探讨普通昏迷及其相关的药理学考量，随后第二部分重点关注脑死亡。结论：准确评估昏迷和脑死亡通常需要多学科方法，整合神经病学、药剂学、重症监护和毒理学的专业知识。目前的脑死亡指南提供了一个框架，但在药理学和毒理学干扰因素方面仍留有关键空白。本综述文章强调了多学科方法在昏迷和脑死亡患者护理中的重要性，并指出需进一步研究以提高诊断准确性并降低过早宣告脑死亡的风险。

### 第二部分 AI 大师评价

本文系统性地探讨了脑死亡判定中复杂的药理学与毒理学挑战，强调了低温、器官功能障碍等生理病理状态对药物清除的影响。其核心价值在于提出了多学科协作的临床路径，有效填补了现行脑死亡指南在处理药物干扰因素方面的关键空白。评价认为该指南对重症监护领域具有极高的临床指导意义，能够有效降低因药物影响导致的脑死亡误判风险。

---

## 6. 翻译标题未提供

**期刊：** 期刊信息缺失
**PMID：** PMID未提供

### 第一部分 原文与翻译

**英文原标题：** 原文标题未提供

> **英文摘要：**
> 原文摘要未提供

> **中文摘要：**
> 翻译摘要未提供

### 第二部分 AI 大师评价

AI评价未提供

---

## 7. 真实世界ICU队列中基于机器学习的慢加急性肝衰竭患者无偏聚类研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41559048)
**期刊：** Nature communications
**PMID：** 41559048
**DOI：** 10.1038/s41467-026-68368-6

### 第一部分 原文与翻译

**英文原标题：** Unbiased clustering of acute-on-chronic liver failure patients using machine learning in a real-world ICU cohort.

> **英文摘要：**
> Acute-on-chronic liver failure is a complex condition with varied definitions, complicating risk stratification and targeted management. We apply unsupervised clustering to data from 1,256 patients with acute-on-chronic liver failure as defined by the North American Association for the Study of End-Stage Liver Disease. We systematically evaluate multiple algorithmic models to enable unbiased cohort stratification and to determine key clustering factors and clinical impacts across clusters. The optimal number of clusters is determined using the Partitioning Around Medoids with Ambiguous Clustering algorithm. The clusters from the best-performing nonnegative matrix factorization algorithm are selected, with the Lee's algorithm demonstrating the best performance. Two distinct clusters are identified, showing markedly different 30-day mortality rates (70.35% vs 26.06%). Importantly, acid-base balance-related variables, including bicarbonate, pH, base excess, lactate, and anion gap, are among the primary clustering drivers. An external validation cohort, a decompensated cirrhosis cohort, and a European Association for the Study of the Liver-Chronic Liver Failure Consortium defined Acute-on-chronic liver failure patients cohort confirm consistent distributions of key clustering variables and divergence in 30-day mortality rates, supporting the role of acid-base balance variables. In summary, we show that the unbiased clustering approach successfully identifies distinct acute-on-chronic liver failure clusters with different mortality risks and emphasizes the critical role of metabolic regulation in acute-on-chronic liver failure outcomes, as well as consistent validation.

> **中文摘要：**
> 慢加急性肝衰竭（ACLF）是一种定义多样且复杂的疾病，这增加了风险分层和精准管理的难度。本研究对1,256名符合北美终末期肝病研究协会定义的慢加急性肝衰竭患者数据应用了无监督聚类分析。我们系统地评估了多种算法模型，以实现无偏的队列分层，并确定关键的聚类驱动因素及其在不同聚类间的临床影响。通过“带有模糊聚类的中心点划分”（PAMAC）算法确定了最佳聚类数量。最终选择了性能最优的非负矩阵分解（NMF）算法的聚类结果，其中Lee算法表现最佳。研究识别出两个截然不同的聚类，其30天死亡率存在显著差异（70.35% vs 26.06%）。重要的是，酸碱平衡相关变量（包括碳酸氢盐、pH、剩余碱、乳酸和阴离子间隙）是主要的聚类驱动因素。通过外部验证队列、失代偿期肝硬化队列以及欧洲肝脏研究协会-慢性肝衰竭联盟定义的ACLF队列，证实了关键聚类变量的分布一致性以及30天死亡率的差异，支持了酸碱平衡变量的作用。总之，本研究表明无偏聚类方法能成功识别具有不同死亡风险的ACLF亚群，并强调了代谢调节在ACLF结局中的关键作用，且该结果在多个队列中得到了验证。

### 第二部分 AI 大师评价

该研究利用无监督机器学习算法对真实世界ICU队列中的慢加急性肝衰竭（ACLF）患者进行了深度表型分析，成功识别出具有显著预后差异的临床亚型。其核心价值在于突破了传统基于器官功能的评价体系，揭示了酸碱平衡及代谢调节指标在ACLF风险分层中的主导驱动作用。研究设计严谨，通过多种算法比较与多中心、跨定义的外部队列验证，确保了结论的稳健性。尽管该分类展现了强大的死亡预测能力，但其临床转化路径以及针对特定代谢表型的干预策略仍需进一步探索。

---

速递结束，祝您工作愉快！